Europa proponit Ban in SAPIDUS Vapes

Sed ortum est vaping — cum suo agmine delibuto cartridges/silicum iuvenum amicabilium, gustat ut bullagum, crème brûlée, menta vel fragum PEPON

annuntiansrogationem to amend existing EU rules, to remove an exemption on the sale of flavored tobacco products that currently applies to e-cigarettes and other heated tobacco products, the Commission said sales volumes of these products had risen at least 10% in at least five Member States, adding that the sales volume of heated tobacco products at retail level now exceeds 2.5% of the total sales of tobacco products at Union level.

Tractans de proposita banno de tabaci calefacto condito productis in constitutione;

Sublato

Parlamentum Europaeum et Consilium necesse est ut rogationem Commissionis perpendat, antequam lex pan-EU fieri possit —, quamvis bannum salubrium saporibus abhorrere videatur, multam oppositionem generare.

Post propositio legislatores co-legum EU’s fauorem obtinet, banus will

Ipsum igitur bannum veri simile esse videtur

Circumspectio finis venditio pomi tabaci leguminis sapidi trans EU’s unicum mercatum de ~450 decies sumptum est, adhuc alius ictu moderante pro e-cigarette mercatus est.

Ante hoc mensisFDA securim in vape deliciae dejecit, Juul â .iubens comitatu whose XXXVIII $ billion in altum, semel aestimatum ledo protervi to stop selling and distributing its e-cigarette devices and tobacco pods in the U.S. entirely, after it failed to provide consistent evidence about the safety of its products.

Societas quaesita et concessa subitis administrativae Veneris sistens moram formalem quaerit dum decisionem FDA appellat.

Paucis ante annis, Juulconstatprohibere vendere siliquas suas suaviter sapidosas e-liquidas €” cum fructu, creme, mango et cucumeris saporibus ut scrutinium regulatorium super curas aetatis usus processit.

In tempore, factor e-cigarette dixit se suam plenam extensionem saporum extra U.S. vendere continuaturum, sed mercatus internationalis minus grate tabaci productorum sapiat.

Haec relatio renovata est ad singulas instantiae administrationis subitis Juul concessae ad appellandum decisionem FDA datam.